Sarepta: Still A Solid Long-Term Bet On Sales And Next Generation Treatments

Terry Chrisomalis
Investing Group Leader

Summary

  • Increase in revenue of $166.9 million observed with FDA approved DMD drugs in Q3 of 2021; year over year increase of 37%.
  • Next-generation PPMO drugs are being advanced in order to improve upon the first generation types; in addition, other mutations observed in DMD are being targeted as well.
  • The pivotal EMBARK study, using SRP-9001 for the treatment of patients with DMD is expected to complete recruitment in 1st half of 2022, with results shortly after.
  • Fully enhanced pipeline with 40+ clinical candidates in development provides many shots on goal.
  • I do much more than just articles at Biotech Analysis Central: Members get access to model portfolios, regular updates, a chat room, and more. Learn More »

Female Laboratory Research Analyst

SolStock/E+ via Getty Images

Sarepta Therapeutics (NASDAQ:SRPT) remains a solid long-term buy in my opinion. There are several reasons why I believe this is going to be the case. The biggest reason of all is that as of today, sales for

This article is published by Terry Chrisomalis, who runs the >Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

This article was written by

Terry Chrisomalis
13.54K Followers

Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare.

He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About SRPT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on SRPT

Related Stocks

SymbolLast Price% Chg
SRPT
--
Compare

Trending Analysis

Trending News